ArticleCell communication and signaling : CCS2026
Peritoneal exosomes mediate activation of CD4
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundExosomes have emerged as promising vaccine candidates due to their role in intercellular communication and bioactive cargo-carrying capacity. However, their intrinsic properties in activating adaptive immunity have not yet been fully addressed. This study aims to elucidate how teleost peritoneal cell-derived exosomes (PDEs) elicit CD4+ T cell activation and contribute to vaccine-mediated adaptive immunity.
methodsPDEs were isolated from flounder immunized with inactivated Vibrio anguillarum (ExoFKC) or non-immunized flounder (ExoCon) via differential centrifugation. Tissue and cellular distribution of DiO-labeled exosomes was visualized and analyzed via small animal imaging, fluorescence microscopy, and flow cytometry. The capacity of PDEs to promote CD4+ T cell activation was assessed using flow cytometry and CFSE assay. Multi-omics approaches were used to analyze ExoFKC-mediated CD4+ T cell activation mechanisms at protein, mRNA, and miRNA levels. CD4+ T cell levels and antibody production were analyzed to assess the impact of ExoFKC on enhancing vaccine potency.
resultsAfter intraperitoneal vaccination, PDEs increased markedly. These exosomes fused with peritoneal cells to facilitate the transport of antigen-presenting molecule locally and were transferred to key lymphoid organs. PDEs carrying T cell-associated RNA (jun/p38a) and miRNA (novel-m0034-3p), with elevated MHCII and CD80/86 levels, promoted CD4⁺ T cell activation. ExoFKC, when used as an adjuvant with the vaccine, enhanced vaccine efficacy by activating CD4⁺ T cells and increasing antibody production.
conclusionsThis study highlights a novel mechanism by which exosomes directly contribute to vaccine-induced immunity, as demonstrated in a lower vertebrate model. It is plausible that similar processes may occur in higher vertebrates, including humans, providing new insights into the role of exosomes in adaptive immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.